Successful therapy of refractory graft versus host disease with tacrolimus and psoralen plus ultraviolet light

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 236-239

  Jubran, Rima F ^a   Dinndorf, Patricia A ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

GVHD; PUVA; Tacrolimus

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHYLPREDNISOLONE; PSORALEN; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PUVA; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FICUSIN; GLOBULINS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; METHYLPREDNISOLONE; PHOTOSENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TACROLIMUS; ULTRAVIOLET THERAPY;

EID: 0031977608     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00017     Document Type: Article

References (12)

1. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
2. Masoka T, Shibata H, Kishita E, et al. Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 1991;23: 3228-31.
3. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 1991;23:3225-7.
4. Koehler MT, Howrie D, Mirro J, et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995;15:895-9.
5. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood 1995;85:3746-53.
6. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporine and/or other immunosuppressants. Bone Marrow Transplant 1995;15:885-9.
7. Fay JW, Wingard JR, Antin JH, et al. FK506 monotherapy for the prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996;87: 3514-9.
8. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996;88: 4383-9.
9. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: Therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995;17:606-14.
10. Nash RA, Storb R. Tacrolimus-based immunosuppression for the prevention of acute GVHD after marrow transplantation. In: Leiberman R, Mukherjee A, ed. Principles of Drug Development in Transplantation and Autoimmunity. Austin: R. G. Landes, 1996;205-10.
11. Kapoor N, Pelligrini AE, Copelan EA, et al. Psoralen plus ultraviolet light A (PUVA) in the treatment of chronic graft versus host disease: Preliminary experience in standard treatment resistant patients. Seminars in Hematology 1992;29:108-12.
12. Aubin F, Brion A, Decininck E, et al. Phototherapy in the treatment of cutaneous graft-versus-host disease: Our preliminary experience in resistant patients. Transplantation 1995;59:151-5.